Hydrocortisel

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hydrocortisel

Property Description
Active Ingredient Dexamethasone, Neomycin
Form Solution, Suspension (Ophthalmic/Otic/Topical)
Pharmacological Class Steroid/Anti-infective Combination
Common Use Managing local inflammation and infection
Origin Synthetic (Dexamethasone), Semi-synthetic (Neomycin)

What Type of Medicine is Hydrocortisel?

Hydrocortisel is classified as a fixed-dose combination product, uniting the potent synthetic corticosteroid Dexamethasone with the aminoglycoside antibiotic Neomycin into a single preparation. This compound belongs to the pharmacological class known as Ophthalmic Steroids with Anti-infectives. Such dual agents are utilized for simplifying the therapeutic approach to conditions requiring simultaneous anti-inflammatory and anti-bacterial activity. This means the medicine is specifically designed to deliver two critical actions simultaneously, intended for the management of localized skin or eye conditions. The product is manufactured as a solution or suspension, primarily intended for localized administration via the ocular, otic, or topical routes.

What is Hydrocortisel Composed of and Where Does It Come From?

The composition features the key active substances Dexamethasone and Neomycin (typically in its sulfate form). Dexamethasone is a highly potent, synthetic glucocorticoid created to provide intense anti-inflammatory effects by suppressing local immune activity. Neomycin is an effective aminoglycoside antibiotic that is semi-synthetic, originating from the bacterial species Streptomyces fradiae. This antibiotic is effective against a broad range of susceptible bacteria, making it suitable for managing typical superficial bacterial infections.

What is the General Purpose of Combining Dexamethasone and Neomycin?

The general purpose of this combination is to provide a comprehensive response to conditions where inflammation and bacterial presence coexist, such as an inflamed outer ear infection. By combining the agents, the medicine aims to quickly mitigate symptoms of swelling and redness using the powerful anti-inflammatory effects of Dexamethasone. Concurrently, the Neomycin component executes a bactericidal action, directly eliminating the susceptible bacterial source. This dual functionality is intended to offer symptomatic relief and manage the infection in a single, localized application, reflecting a strategic approach to therapy.

Regulatory References

  1. NIH/MedlinePlus

What side effects are possible with Hydrocortisel?

Possible side effects and safety information

The official regulatory documents for the Dexamethasone/Neomycin combination describe the documented adverse reactions and specific safety patterns, which are primarily related to the localized administration of the product.

Adverse reactions associated with the corticosteroid component (Dexamethasone) largely fall under Eye Disorders, including potential elevation of intraocular pressure (IOP), which may lead to glaucoma and, infrequently, optic nerve damage. Posterior subcapsular cataract formation and delayed wound healing are also officially listed. Systemic effects, such as Cushing's syndrome and adrenal suppression, have been identified as serious adverse reactions following intensive or long-term continuous therapy due to potential absorption.

Reactions associated with the Neomycin component most often present as allergic sensitizations, leading to cutaneous sensitization, erythema, itching, and skin rash. Hypersensitivity can, in rare cases, involve severe reactions like anaphylaxis or Stevens-Johnson syndrome.

Time- and Duration-Related Safety Patterns emphasize that prolonged use is associated with increased risks of glaucoma, cataracts, and secondary ocular infections. The product's safety profile also notes Population-Specific Safety Considerations: safety and effectiveness have not been established in pediatric patients, and caution is advised regarding use in pregnant women and nursing mothers.

Overdose and Emergency Response

A single, large overdose of Hydrocortisel (hydrocortisone) is rarely life-threatening but can lead to acute, noticeable side effects. Prolonged misuse or use of very high doses over time can result in more serious complications.

Acute Overdose Symptoms

Symptoms that may follow a significant, single overdose include, but are not limited to, those related to fluid and electrolyte imbalance. These effects are often transient but should still be monitored.

System Possible Symptoms
Metabolic High blood sugar (hyperglycemia)
Cardiovascular High blood pressure (hypertension), fluid retention
Psychiatric Agitation, nervousness, depression, or psychosis
Gastrointestinal Nausea or vomiting

When to Seek Help

Immediate medical attention is necessary if you suspect an overdose of Hydrocortisel or if you experience severe symptoms. Contact emergency medical services or a poison control center immediately.

Consult a healthcare provider if you experience signs of severe or prolonged side effects, especially if using the medication long-term. These include persistent mood changes, unusual weight gain, a puffy rounded face (Cushingoid features), severe stomach pain, or new signs of infection such as fever or persistent sore throat. Never stop the medication abruptly without professional guidance, particularly after prolonged use, as this can lead to adrenal insufficiency.

Therapeutic Uses of Hydrocortisel

What Hydrocortisel treats: main uses and benefits

Hydrocortisel is a medication utilized to help manage symptoms associated with various conditions characterized by inflammation or immune system overactivity. The medication is also employed to address certain hormonal deficiencies. Its therapeutic role is to support the management of symptoms by addressing underlying inflammatory and immune responses.

Clinical situations where Hydrocortisel is commonly used include, but are not limited to, different types of arthritis, severe allergic responses, and conditions affecting the skin, lungs, eyes, blood, and intestines. The primary benefit is that it may offer assistance with uncomfortable symptoms such as pain, swelling, and itching. A brief enumeration of indications includes endocrine, rheumatic, and collagen disorders, along with certain dermatologic, allergic, ophthalmic, respiratory, hematologic, and gastrointestinal diseases.


Quick Fact: May help address symptoms of inflammation and immune disorders.


Eligibility and Restrictions for Use

Eligibility Profile: Official Regulatory Information

Hydrocortisel, which contains the active substance hydrocortisone, has a defined eligibility profile based strictly on official regulatory documents such as Prescribing Information and Summary of Product Characteristics (SmPC). This profile determines who can and cannot use the medicine.

Populations That Must Not Use (Contraindicated):

Official labeling strictly prohibits the use of hydrocortisone for patients with a Systemic Fungal Infection or a known Hypersensitivity to the drug or its components. Specific injection routes, such as Intrathecal or Epidural administration, are also contraindicated due to documented serious risks.

Populations Requiring Conditional or Restricted Use:

Pregnancy and Lactation: Use is restricted to situations where the clinical benefit clearly outweighs the potential risk to the fetus or infant, due to insufficient data or documented animal risks.

Pediatric Patients: Children, particularly infants, face a greater risk of systemic side effects (such as HPA axis suppression) from both systemic and topical use. Topical use must be carefully monitored and restricted to the minimum effective amount.

Comorbidities: Use requires caution and close monitoring in individuals with conditions like Diabetes Mellitus, Hypertension, Active Infections (e.g., ocular herpes simplex, tuberculosis), or Gastrointestinal Disorders (e.g., peptic ulceration), as the medicine can aggravate these conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction scope

Medicinal product categories with documented interactions: Strong CYP3A4 Inhibitors, Live or Live, Attenuated Vaccines, Ophthalmic Nonsteroidal Anti-Inflammatory Agents (NSAIDs), Potentially Neurotoxic/Nephrotoxic Drugs, Neuromuscular Blocking Agents/Anesthetics, Potent Diuretics. Specific interacting medicines (if explicitly listed): Ritonavir, Nirmatrelvir, and Botulinum Toxins. Mechanistic basis of interactions (only if stated in label): Metabolic Inhibition of Dexamethasone; Pharmacodynamic Synergism/Additive Toxicity from Neomycin; Pharmacodynamic Antagonism with live vaccines. Timing-based interaction rules (if applicable): None explicitly documented for mandatory separation time. Population-specific interaction notes (if applicable): Children and Predisposed Patients using Strong CYP3A4 Inhibitors are noted to have a heightened risk of systemic effects from increased Dexamethasone exposure. Interaction-related restrictions: Formal Contraindication against co-administration with live or live, attenuated vaccines; Avoid concurrent and/or sequential use with other neurotoxic or nephrotoxic drugs.


Interaction classifications (high-level)

Interaction severity classification (as defined in official documents): Contraindicated Combination (Vaccines); Clinically Significant Interaction (CYP3A4 Inhibitors, Toxicity Agents). Regulatory basis: Information is derived from FDA Prescribing Information and EMA/National Monograph data for the active components. Interaction-context constraints: Constraints are due to potential systemic exposure of the corticosteroid and class effects of the aminoglycoside antibiotic.


Resulting interaction structure

Official interaction statements:

  • Live or Live, Attenuated Vaccines: Co-administration is formally contraindicated in patients receiving immunosuppressive doses of the corticosteroid component.
  • Strong CYP3A4 Inhibitors: These agents may increase the systemic plasma concentration of Dexamethasone, which can lead to a risk of systemic effects.
  • Potentially Neurotoxic or Nephrotoxic Drugs: Concurrent or sequential use must be avoided due to the potential for additive toxicity (enhanced nephrotoxicity and/or ototoxicity) from the Neomycin component.
  • Neuromuscular Blocking Agents: The Neomycin component may potentiate the effects of these agents, carrying a risk of neuromuscular blockade.
  • Ophthalmic Nonsteroidal Anti-Inflammatory Agents (NSAIDs): Combining ophthalmic NSAIDs may increase the risk of adverse ocular effects, specifically involving delayed tissue healing.

Connection to the overall interaction profile (2–4 sentences): The regulatory interaction profile identifies substances that significantly modify drug exposure or carry an additive toxicity risk. The profile officially documents combinations that are strictly contraindicated alongside those requiring avoidance or caution due to clinically significant effects on drug levels or potential synergistic toxicity. This establishes the necessary boundaries for co-administration as defined by government regulatory agencies.

Mechanism of Action

How Hydrocortisel Works

Hydrocortisel is a synthetic corticosteroid that modulates key immunological and metabolic pathways. Its mechanism involves binding to the cytoplasmic glucocorticoid receptor (GR), a member of the nuclear receptor superfamily. Upon binding, the activated GR complex translocates into the nucleus, where it functions as a ligand-dependent transcription factor. In the nucleus, it acts primarily through two principal mechanisms: transactivation and transrepression.

Through transrepression, the activated GR complex physically interacts with other transcription factors, such as NF-kappaB and AP-1, to inhibit their activity. This action reduces the transcription of pro-inflammatory genes, including those encoding cytokines (e.g., IL-1beta, TNF-alpha), chemokines, and adhesion molecules. This cascade limits the inflammatory cascade.

Conversely, through transactivation, the GR complex binds to specific glucocorticoid response elements (GREs) in the promoter regions of target genes, increasing their transcription. Key genes activated include those encoding anti-inflammatory proteins, such as annexin A1 (lipocortin-1) and glucocorticoid-induced leucine zipper (GILZ), which mediates cell membrane integrity and metabolic homeostasis.

The overall consequence of this dual action is modification of the body's response to inflammation and stress.

Dosage and Administration Information

How to use Hydrocortisel

Hydrocortisel (hydrocortisone) is used via multiple routes, primarily oral for chronic conditions and intravenous (IV) or intramuscular (IM) for acute or emergent care. Dosage and administration are typically individualized based on the specific condition and the patient's response.

Administration Details

  • Route of Administration: Oral (tablets, granules) for maintenance therapy; Intravenous or Intramuscular injection for acute/emergency situations.
  • Dosing Schedule: For chronic replacement therapy, a common dose is 20 mg to 30 mg per day, typically given in two or three divided doses to mimic the body's natural cortisol rhythm. The largest portion of the daily dose is generally taken in the morning. Acute dosing is much higher, often starting at 100 mg to 500 mg IV, which may be repeated as necessary.
  • Timing: Oral tablets or granules should be taken with or immediately after food or milk to reduce gastric irritation.

Procedural and Special Conditions

  • Preparation for Injection: The sterile powder for injection must be reconstituted by adding no more than 2 mL of Bacteriostatic Water for Injection or Sodium Chloride Injection, and then gently agitated to ensure complete dissolution. Further dilution is required for intravenous infusion.
  • Age-Specific Use: Pediatric dosing for chronic adrenal insufficiency is typically governed by the severity of the condition and patient response, not solely by age or weight, but should not be less than 25 mg daily.
  • Missed Dose: If a dose is missed, it should be taken as soon as possible, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped. Do not double a dose to compensate.
  • Stress Dosing: In times of physical or mental stress (e.g., severe illness, surgery, trauma), the dose is temporarily increased, sometimes 3 to 5 times the maintenance dose, under the guidance of a healthcare professional. Following long-term therapy, the drug is withdrawn gradually to allow the body to recover, rather than abruptly stopped.

Instruction Classifications
Administration Method Type Oral, Intravenous, Intramuscular
Frequency Pattern Multiple doses daily; As-needed (for acute stress)
Basis Clinical guidelines

Recent Clinical Evidence

Hydrocortisel: Recent Clinical Evidence


Evidence for Use in Adrenal Insufficiency

Studies have been conducted to evaluate Hydrocortisel in individuals with adrenal insufficiency, a condition characterized by functional imbalance. Research primarily involves short-term clinical trials that monitored outcomes related to systemic function in adult populations. The findings describe results observed during the study periods and highlight measurements related to how physiological imbalance was tracked. The evidence contributes to the broader evidence landscape, but the findings reflect only the specific populations that were included.


Evidence for Use in Inflammatory Conditions

Hydrocortisel was evaluated in research exploring its applications in various inflammatory conditions which may involve periods of heightened symptoms. Research has explored its use through short-term controlled clinical trials examining outcomes related to physical discomfort and inflammatory states. Findings were mixed across various studies, and the overall evidence for this application remains limited and heterogeneous.


Long-term Studies and Follow-up

Research exploring the long-term outcomes associated with Hydrocortisel is an area where evidence is limited. Most existing studies focus on short-term symptom changes and have limited follow-up durations. This means that long-term outcomes are not well characterized. Data for extended follow-up often come from observational cohorts, which provide context but differ in structure from long-term controlled trials.


Evidence in Special Populations

Current research has largely concentrated on general adult populations, and as a result, data for certain groups remain insufficient. Few data are available for populations such as children or older adults in the research contexts involving this product. Additionally, limited information is available for individuals with certain complex co-morbid conditions.


What Is Still Uncertain About Hydrocortisel

The current body of research highlights several areas where more information is needed. A major gap is the lack of data describing long-term outcomes. Evidence quality varies across studies, and many of the trials conducted have employed modest sample sizes, contributing to low certainty overall. Furthermore, inconsistent findings have been reported across different studies and conditions. Comparative evidence is lacking in several areas.

Frequently Asked Questions (FAQ)

Common questions about Hydrocortisel (FAQ)

Q: Is Hydrocortisel the same type of medicine as regular cortisone?

A: No, Hydrocortisel is a fixed-dose combination product containing the potent synthetic corticosteroid Dexamethasone and the antibiotic Neomycin. Cortisone, or hydrocortisone, is a different corticosteroid component. Official documents describe Hydrocortisel’s function as combining both a strong anti-inflammatory agent and an antibiotic into one preparation.


Q: What is the main difference between Hydrocortisel and other common steroid creams?

A: The primary difference is that official documents classify Hydrocortisel as a fixed-dose combination product. This means it is designed to deliver two active components—a potent anti-inflammatory steroid (Dexamethasone) and an antibiotic (Neomycin)—in a single preparation. Many other common topical products contain only the steroid component.


Q: Do I need a prescription to get Hydrocortisel?

A: Yes, regulatory documentation confirms that Hydrocortisel, which contains Dexamethasone and Neomycin, is classified as a prescription-only medicine. It is not available for purchase without authorization from a healthcare professional.


Q: Can Hydrocortisel be used for any kind of skin rash or just specific conditions?

A: Official labeling specifies that Hydrocortisel is indicated only for certain steroid-responsive inflammatory conditions where there is an existing or anticipated risk of bacterial infection. Its use is limited to the specific conditions identified and approved in the regulatory labeling.


Q: Is it normal to feel a slight burning sensation when first applying Hydrocortisel?

A: Official safety information for similar formulations reports that side effects such as local burning, stinging, irritation, or itching have been experienced by some individuals at the application site. If discomfort is severe or persists, consultation with a healthcare professional is consistent with official guidance.


Q: Are there any long-term health concerns from using Hydrocortisel occasionally?

A: Regulatory documents primarily focus on health risks associated with intensive or long-term continuous therapy, which can lead to serious systemic effects like cataracts, glaucoma, and adrenal suppression. Risks associated with occasional, short-term use are not specifically detailed in the same context as prolonged use.


Q: Is Hydrocortisel safe to use during pregnancy or while breastfeeding?

A: Official regulatory documents generally advise that the product is not recommended during pregnancy unless the potential benefit to the mother is judged to outweigh the potential risk. Furthermore, a decision must be made to either discontinue the drug or discontinue nursing, taking into account the drug's importance to the nursing mother.


Q: Do I have to avoid sunlight completely while using Hydrocortisel?

A: Some official documentation lists sensitivity to light (photosensitivity) as a possible side effect of the corticosteroid component. Patients who experience this reaction may become more sensitive to sun or light exposure.


Q: What are the signs that I should stop using Hydrocortisel and call a healthcare professional?

A: Official patient safety information advises stopping the medication if inflammation or pain persists for longer than 48 hours or becomes aggravated. Similarly, signs of any serious adverse reactions, such as a severe rash or swelling, warrants consultation with a healthcare professional.


Q: Is there a risk of withdrawal symptoms when stopping Hydrocortisel after short use?

A: Regulatory documents highlight concerns about withdrawal, such as adrenocortical insufficiency, primarily when the product is discontinued after long-term therapy. Regulatory documents note that use of the lowest possible effective dose aligns with official guidance intended to reduce potential risks.


Q: Can applying too much Hydrocortisel cause more side effects?

A: Official regulatory documents advise that the lowest possible dose of corticosteroid should be used to control the condition. This guidance is in place because complications associated with this class of medicine are known to be dependent on both the size of the dose and the duration of treatment.


Q: What should I do if a small child accidentally swallows Hydrocortisel cream?

A: Official patient safety information advises contacting a Poison Control Center or seeking emergency medical help immediately if accidental ingestion is suspected.


Q: Are there any foods or dietary supplements that interact with Hydrocortisel?

A: Official drug interaction lists focus primarily on interactions with other medicinal products, particularly certain enzymes and inhibitors. There is no mention of specific foods or common dietary supplements being known interactants in the core regulatory documents.


Q: What are the typical storage recommendations for Hydrocortisel (temperature, humidity)?

A: The medicine is required to be stored at a temperature not exceeding 25 C or 30 C and must be protected from freezing. It should always be kept in the original, tightly closed container and protected from excessive heat.


Q: Is it okay to use Hydrocortisel under a bandage or tight clothing?

A: Regulatory documents suggest that methods which promote systemic absorption of the topical corticosteroid, such as use under occlusive dressings or tight bandages, may increase the risk of systemic side effects, like those on the adrenal glands.


Q: Can people with diabetes use Hydrocortisel safely?

A: Official documentation advises that individuals with Diabetes Mellitus should use the product with caution and require close monitoring. This is because the risk of corticosteroid-induced side effects, such as elevated intraocular pressure, is greater in those with pre-existing conditions like diabetes.


Q: What if the condition I am treating with Hydrocortisel seems to get worse?

A: Official patient information recommends that if the condition being treated becomes aggravated or if signs of a new infection develop, the medication should be stopped. When this occurs, consultation with a healthcare professional is consistent with regulatory guidance.


Q: Does Hydrocortisel have any known side effects on mood or sleep?

A: When absorbed into the body (systemically), the corticosteroid component has been listed in official side-effect summaries as being associated with a wide range of psychiatric reactions and sleep disturbances, such as insomnia.


Q: How soon after starting treatment might I see a doctor for a follow-up visit?

A: Official labeling advises that if the product is used for 10 days or longer, the patient's intraocular pressure (IOP) should be routinely monitored. Such monitoring necessitates regular follow-up visits with a healthcare professional.


Q: If Hydrocortisel is treating inflammation, can it also help with pain?

A: The corticosteroid component is a strong anti-inflammatory agent, which works to diminish edema and inflammation. While it is not specifically classified as a pain reliever, inflammation is a known source of pain.


Q: Why is it recommended to use the lowest effective dose of Hydrocortisel?

A: Regulatory documents explicitly state that the lowest possible dose of corticosteroid should be used to manage the condition. This is because the risk of complications from treatment is dependent on both the size of the dose and the duration of its use.


Q: Are there specific parts of the body where Hydrocortisel should never be applied?

A: Official labeling prohibits use in the presence of most viral diseases of the cornea or conjunctiva (like Herpes Simplex), as well as any mycobacterial or fungal infections of the ocular structures. Its use must be restricted based on the presence of certain infection types.


Q: Can I use moisturizing lotions or creams right before or after applying Hydrocortisel?

A: Regulatory warnings focus on interactions with other medicated products. There is no specific instruction in official documents about the sequential use of non-medicated moisturizing lotions or creams.


Q: What is the risk of skin infection while using Hydrocortisel?

A: Official warnings state that prolonged use of the corticosteroid component may suppress the local immune response. This suppression can increase the hazard of secondary infections, including fungal infections, in the area of application.


Q: Can Hydrocortisel be used by people with compromised immune systems?

A: Regulatory documents note that the corticosteroid component can cause immunosuppression, and prolonged use may increase the incidence of secondary infections. Official information indicates that use should proceed with caution and close monitoring, given the potential for immune effects.


Q: Is Hydrocortisel absorbed into the bloodstream, and if so, how much?

A: The labeling indicates that a risk of systemic absorption is possible, especially with intensive or long-term continuous use, leading to potential side effects like adrenal gland suppression. The exact amount of absorption is variable and not typically quantified in general patient information.


Q: Do healthcare providers need special training to prescribe Hydrocortisel?

A: The official documentation does not mandate specific training, but it does advise that the initial prescription and renewal should only be made by a physician after a thorough examination of the patient using appropriate magnification (e.g., slit lamp biomicroscopy).


Q: How does the concentration of Hydrocortisel influence its strength?

A: Official documentation notes that the overall potency of the corticosteroid component is dependent on multiple factors. These factors include the drug's molecular structure, the specific formulation's concentration, and how well the active ingredient is released from the vehicle (suspension or ointment).


Q: What are the official regulatory approvals for Hydrocortisel's specific uses?

A: The product is officially approved for the management of steroid-responsive inflammatory ocular conditions. These are conditions where a corticosteroid is indicated and where a bacterial infection or a specific risk of bacterial ocular infection also exists.


Q: Does Hydrocortisel come in different formulations (e.g., ointment vs. cream)?

A: Official dosage forms include a sterile suspension (often known as drops) and a sterile ophthalmic ointment. These different forms are designed for localized application to the eye or ear.


Q: Can children use Hydrocortisel, and are there different strength limits for them?

A: Official documentation states that the risk of corticosteroid-induced side effects, such as elevated eye pressure, may be greater in children and may occur earlier than in adults. Therefore, its use requires close monitoring and caution in the pediatric population.


Q: What research exists about the effectiveness of Hydrocortisel in older adults?

A: Regulatory documents indicate that no overall differences in safety or effectiveness were observed between older and younger patients in the specific clinical studies reviewed. Generally, no dosage adjustment is considered necessary for the geriatric population.


Q: Is it true that Hydrocortisel can thin the skin if used for a long time?

A: The corticosteroid component has been associated with effects such as delayed wound healing and thinning of the cornea or sclera when used in diseases that cause tissue thinning. Regulatory warnings focus on these risks related to prolonged use.

How should Hydrocortisel be stored and disposed of?

Storing and Disposing of Hydrocortisel

The storage and disposal requirements for Hydrocortisel (Dexamethasone/Neomycin) are governed by official regulatory labeling to ensure product quality and safety.


Storage Requirements

Hydrocortisel must be stored at a temperature below 25 C or 30 C and protected from freezing. The suspension/drops formulation should not be refrigerated. The product must be stored in the original container, which should be kept tightly closed, and protected from excessive heat and direct light.

Stability and Safety

Once the container is opened, the product has a limited in-use shelf-life and must be discarded after 28 days to prevent contamination. The medicine must always be stored out of the sight and reach of children.

Disposal

Unused or expired Hydrocortisel must be disposed of in accordance with local requirements, and should not be discarded via household waste or wastewater where collection programs are available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hydrocortisel found in:

A-Z Index: